About Seagen Inc. (SGEN)

Company Description:

Seagen Inc., a biotechnology company, is pioneering the field of targeted therapies to treat cancer. The company focuses on developing and commercializing a new class of therapies called antibody-drug conjugates (ADCs). These novel treatments are designed to target and destroy cancer cells while sparing healthy cells, offering a more precise approach to cancer therapy.

Founded in 1998, Seagen Inc., originally known as Seattle Genetics, is headquartered in Bothell, Washington, United States. The company has established itself as a leader in the ADC technology, making significant strides in cancer treatment.

Main Product(s):

Seagen's key products include ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), and TIVDAK® (tisotumab vedotin-tftv), all of which are used in various treatments for different types of cancer.

Short History of Seagen Inc:

• 1998 – Seagen was founded, focusing on cancer therapy innovation.
• 2001 – The company went public on the NASDAQ stock exchange.
• 2011 – ADCETRIS®, its first ADC product, received FDA approval.
• 2020 – Seagen broadened its reach by gaining FDA approvals for TUKYSA® and TIVDAK®.
• 2021 – Continued expansion in the ADC field with further research and collaborations.